Literature DB >> 11576528

Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages.

K L Carpenter1, I F Dennis, I R Challis, D P Osborn, C H Macphee, D S Leake, M J Arends, M J Mitchinson.   

Abstract

The death of macrophages contributes to atheroma formation. Oxidation renders low-density lipoprotein (LDL) cytotoxic to human monocyte-macrophages. Lipoprotein-associated phospholipase A2 (Lp-PLA2), also termed platelet-activating factor acetylhydrolase, hydrolyses oxidised phospholipids. Inhibition of Lp-PLA2 by diisopropyl fluorophosphate or Pefabloc (broad-spectrum serine esterase/protease inhibitors), or SB222657 (a specific inhibitor of Lp-PLA2) did not prevent LDL oxidation, but diminished the ensuing toxicity and apoptosis induction when the LDL was oxidised, and inhibited the rise in lysophosphatidylcholine levels that occurred in the inhibitors' absence. Hydrolysis products of oxidised phospholipids thus account for over a third of the cytotoxic and apoptosis-inducing effects of oxidised LDL on macrophages.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11576528     DOI: 10.1016/s0014-5793(01)02840-x

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  26 in total

Review 1.  Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.

Authors:  Robert S Rosenson; Diana M Stafforini
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

2.  Cloning, expression, and purification of lipoprotein-associated phospholipase A(2) in Pichia pastoris.

Authors:  Fujun Zhang; Yiping Wang
Journal:  Mol Biotechnol       Date:  2006-05       Impact factor: 2.695

Review 3.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Authors:  Edward A Dennis; Jian Cao; Yuan-Hao Hsu; Victoria Magrioti; George Kokotos
Journal:  Chem Rev       Date:  2011-09-12       Impact factor: 60.622

4.  Lipoprotein-associated phospholipase A2, C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuria.

Authors:  Rachel G Miller; Tina Costacou; Trevor J Orchard
Journal:  Diab Vasc Dis Res       Date:  2009-10-28       Impact factor: 3.291

5.  Translational studies of lipoprotein-associated phospholipase A₂ in inflammation and atherosclerosis.

Authors:  Jane F Ferguson; Christine C Hinkle; Nehal N Mehta; Roshanak Bagheri; Stephanie L Derohannessian; Rhia Shah; Megan I Mucksavage; Jonathan P Bradfield; Hakon Hakonarson; Xuexia Wang; Stephen R Master; Daniel J Rader; Mingyao Li; Muredach P Reilly
Journal:  J Am Coll Cardiol       Date:  2012-02-21       Impact factor: 24.094

Review 6.  Lp-PLA(2) as a marker of cardiovascular diseases.

Authors:  Sabha Bhatti; Abdul Hakeem; Mehmet Cilingiroglu
Journal:  Curr Atheroscler Rep       Date:  2010-03       Impact factor: 5.113

Review 7.  The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis.

Authors:  Salim S Virani; Vijay Nambi
Journal:  Curr Atheroscler Rep       Date:  2007-08       Impact factor: 5.113

8.  The elevation of apoB in hypercholesterolemic patients is primarily attributed to the relative increase of apoB/Lp-PLA₂.

Authors:  Constantinos C Tellis; Eliza Moutzouri; Moses Elisaf; Robert L Wolfert; Alexandros D Tselepis
Journal:  J Lipid Res       Date:  2013-10-03       Impact factor: 5.922

9.  Chronic hyperglicemia and nitric oxide bioavailability play a pivotal role in pro-atherogenic vascular modifications.

Authors:  Assunta Pandolfi; Elena Anna De Filippis
Journal:  Genes Nutr       Date:  2007-10-17       Impact factor: 5.523

10.  Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community.

Authors:  Yariv Gerber; Shannon M Dunlay; Allan S Jaffe; Joseph P McConnell; Susan A Weston; Jill M Killian; Véronique L Roger
Journal:  Atherosclerosis       Date:  2008-08-07       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.